https://scholars.lib.ntu.edu.tw/handle/123456789/496090
標題: | Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus | 作者: | CHIN-HSIAO TSENG | 公開日期: | 2014 | 出版社: | Elsevier Ltd | 卷: | 50 | 期: | 16 | 起(迄)頁: | 2831-2837 | 來源出版物: | European Journal of Cancer | 摘要: | Background Whether metformin therapy affects incident prostate cancer risk in Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated. Methods The National Health Insurance reimbursement database of Taiwanese male patients with new-onset T2DM between 1998 and 2002 and aged ?40 years (n = 395,481) were retrieved to follow up prostate cancer incidence until the end of 2009. Metformin was treated as a time-dependent variable. Of the patients studied, 209,269 were never-users and 186,212 were ever-users. A time-dependent approach was used to calculate prostate cancer incidence and estimate hazard ratios using Cox regression for ever-users, never-users and subgroups of metformin exposure (tertiles of cumulative duration and cumulative dose). Sensitivity analyses were conducted in various subgroups, using time-dependent and non-time-dependent approaches. Results During the follow-up, 2776 metformin ever-users and 9642 never-users developed prostate cancer, representing an incidence of 239.42 and 737.10 per 100,000 person-years, respectively. The hazard ratio (95% confidence intervals) after adjustment for propensity score (PS) for ever- versus never-users was 0.467 (0.446-0.488). The PS-adjusted hazard ratios for the first, second and third tertiles of cumulative duration of metformin therapy were 0.741 (0.698-0.786), 0.474 (0.441-0.508) and 0.231 (0.212-0.253), respectively (P-trend < 0.001); and were 0.742 (0.700-0.786), 0.436 (0.406-0.468) and 0.228 (0.208-0.251) for the respective cumulative dose (P-trend < 0.001). Sensitivity analyses consistently supported a protective effect of metformin on incident prostate cancer. Conclusions Metformin use is associated with a decreased risk of incident prostate cancer in Taiwanese male patients with T2DM. ? 2014 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925395989&doi=10.1016%2fj.ejca.2014.08.007&partnerID=40&md5=21d53a0e9f94a91b7b862d10e037dbc1 https://scholars.lib.ntu.edu.tw/handle/123456789/496090 |
ISSN: | 0959-8049 | DOI: | 10.1016/j.ejca.2014.08.007 | SDG/關鍵字: | metformin; antidiabetic agent; metformin; adult; Article; cancer incidence; cancer prevention; cancer risk; cohort analysis; dose time effect relation; follow up; human; major clinical study; male; middle aged; non insulin dependent diabetes mellitus; population research; priority journal; prostate cancer; retrospective study; sensitivity analysis; Taiwanese; treatment duration; aged; complication; Diabetes Complications; Diabetes Mellitus, Type 2; incidence; proportional hazards model; Prostatic Neoplasms; risk factor; Taiwan; treatment outcome; Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taiwan; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。